High efficacy and drug synergy of hdac6-selective inhibitor nn-429 in natural killer (nk)/t-cell lymphoma

HIGHLIGHTS

  • who: Harsimran Kaur Garcha and collaborators from the Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga Road, Mississauga, ON L L , Canada have published the research: High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma, in the Journal: Pharmaceuticals 2022, 15, x FOR PEER REVIEW of 26/Oct/2022
  • what: Given these clinical needs, particularly for the incurable, aggressive, and rare entities of u03b3u03b4 T-NHL and NKTCLs, the authors aimed to design an HDAC6 inhibitor with drug-like properties, explored here via . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?